Wave Cash Conversion Cycle vs Ev To Free Cash Flow Analysis
WVE Stock | USD 14.27 0.08 0.56% |
Wave Life financial indicator trend analysis is more than just analyzing Wave Life Sciences current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Wave Life Sciences is a good investment. Please check the relationship between Wave Life Cash Conversion Cycle and its Ev To Free Cash Flow accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Cash Conversion Cycle vs Ev To Free Cash Flow
Cash Conversion Cycle vs Ev To Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Wave Life Sciences Cash Conversion Cycle account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Wave Life's Cash Conversion Cycle and Ev To Free Cash Flow is -0.12. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Wave Life Sciences, assuming nothing else is changed. The correlation between historical values of Wave Life's Cash Conversion Cycle and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Wave Life Sciences are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Cash Conversion Cycle i.e., Wave Life's Cash Conversion Cycle and Ev To Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.12 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cash Conversion Cycle
Ev To Free Cash Flow
A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.Most indicators from Wave Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Wave Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. As of November 23, 2024, Selling General Administrative is expected to decline to about 33.7 M. The current year's Tax Provision is expected to grow to about (643.1 K)
Wave Life fundamental ratios Correlations
Click cells to compare fundamentals
Wave Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Wave Life fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 284.3M | 279.2M | 207.0M | 146.4M | 274.9M | 200.5M | |
Short Long Term Debt Total | 32.5M | 29.3M | 29.9M | 37.6M | 32.1M | 20.4M | |
Other Current Liab | 16.2M | 8.3M | 9.9M | 12.1M | 10.1M | 8.5M | |
Total Current Liabilities | 118.2M | 121.0M | 64.2M | 71.5M | 186.4M | 195.8M | |
Total Stockholder Equity | 63.7M | 82.8M | 32.5M | (45.1M) | 47.5M | 49.3M | |
Other Liab | 65.2M | 42.0M | 77.5M | 80.0M | 92.0M | 96.6M | |
Property Plant And Equipment Net | 54.5M | 45.4M | 40.6M | 44.1M | 35.7M | 30.2M | |
Current Deferred Revenue | 89.7M | 91.6M | 37.1M | 31.6M | 150.1M | 157.6M | |
Net Debt | (114.6M) | (155.2M) | (120.6M) | (50.9M) | (168.2M) | (176.6M) | |
Retained Earnings | (533.4M) | (683.3M) | (805.5M) | (967.3M) | (1.0B) | (973.6M) | |
Accounts Payable | 9.1M | 13.8M | 7.3M | 16.9M | 12.8M | 8.9M | |
Cash | 147.2M | 184.5M | 150.6M | 88.5M | 200.4M | 140.1M | |
Non Current Assets Total | 98.8M | 49.2M | 44.4M | 47.8M | 39.6M | 42.5M | |
Other Assets | 44.3M | 3.8M | 3.8M | 3.7M | 4.3M | 4.1M | |
Cash And Short Term Investments | 147.2M | 184.5M | 150.6M | 88.5M | 200.4M | 140.1M | |
Net Receivables | 10M | 20M | 30M | 0.0 | 21.1M | 22.1M | |
Common Stock Total Equity | 539.5M | 694.1M | 749.9M | 802.8M | 923.3M | 969.4M | |
Common Stock Shares Outstanding | 33.9M | 39.2M | 51.8M | 78.9M | 106.1M | 111.4M | |
Liabilities And Stockholders Equity | 284.3M | 279.2M | 207.0M | 146.4M | 274.9M | 200.5M | |
Non Current Liabilities Total | 102.4M | 75.4M | 110.3M | 120.0M | 41.0M | 59.0M | |
Other Current Assets | 8.7M | 15.5M | 12M | 10.0M | 13.9M | 8.7M | |
Total Liab | 220.5M | 196.5M | 174.5M | 191.5M | 227.4M | 132.8M | |
Property Plant And Equipment Gross | 54.5M | 45.4M | 40.6M | 44.1M | 78.4M | 82.4M | |
Total Current Assets | 185.5M | 230.0M | 162.6M | 98.5M | 235.4M | 158.0M | |
Accumulated Other Comprehensive Income | 267K | 389K | 181K | (29K) | (124K) | (117.8K) | |
Short Term Debt | 3.2M | 7.4M | 9.9M | 11.0M | 13.4M | 14.1M | |
Common Stock | 539.5M | 694.1M | 749.9M | 802.8M | 935.4M | 481.8M | |
Property Plant Equipment | 54.5M | 29.2M | 22.3M | 17.3M | 19.9M | 22.5M | |
Net Tangible Assets | 63.7M | 90.7M | 40.4M | (37.2M) | (33.5M) | (31.8M) | |
Other Stockholder Equity | 49.4M | 63.7M | 80.1M | 111.6M | 129.2M | 135.7M | |
Non Currrent Assets Other | 10.7M | 115K | 148K | 62K | 3.9M | 6.9M | |
Capital Surpluse | 57.3M | 71.6M | 88.0M | 119.4M | 137.4M | 144.2M | |
Capital Lease Obligations | 32.5M | 29.3M | 29.9M | 37.6M | 32.1M | 21.5M | |
Non Current Liabilities Other | 1.7M | 67.5M | 102.4M | 112.1M | 128.9M | 135.3M | |
Net Invested Capital | 63.7M | 82.8M | 32.5M | (45.1M) | 39.6M | 44.2M | |
Net Working Capital | 67.3M | 109.0M | 98.4M | 27.0M | 48.9M | 63.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Wave Life Sciences is a strong investment it is important to analyze Wave Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Wave Life's future performance. For an informed investment choice regarding Wave Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Wave Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Wave Life. If investors know Wave will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Wave Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.427 | Quarterly Revenue Growth (0.11) | Return On Assets (0.34) | Return On Equity (2.44) |
The market value of Wave Life Sciences is measured differently than its book value, which is the value of Wave that is recorded on the company's balance sheet. Investors also form their own opinion of Wave Life's value that differs from its market value or its book value, called intrinsic value, which is Wave Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Wave Life's market value can be influenced by many factors that don't directly affect Wave Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Wave Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Wave Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Wave Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.